Invasive Pneumococcal Disease in New Zealand, 2010

More documents

Recommendations

Info

Appendix 10. Penicillin and cefotaxime MIC distribution of pneumococci from invasive disease, 2010Percent of isolates with an MIC (mg/L) of: 10.008 0.016 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16penicillin 1.4 47.9 30.9 1.8 1.6 1.0 3.1 6.4 5.1 1.0cefotaxime 1.8 65.0 13.0 1.9 1.8 1.8 6.6 6.2 0.4 1.0 0.4 0.21 Shaded cells represent MICs that are categorised as penicillin resistant or cefotaxime non-susceptible (intermediate and resistant), based on themeningitis interpretations: penicillin resistant, MIC ≥0.12 mg/L; cefotaxime intermediate, MIC 1 mg/L; and cefotaxime resistant, MIC ≥2 mg/L.Invasive pneumococcal disease 36 September 2011in NZ, 2010
Appendix 11. Trends in penicillin resistance, cefotaxime resistance and multidrug resistance among pneumococcifrom invasive disease, 2001-2010YearNumberofisolatesPenicillinCefotaximeMeningitis 1 Non-meningitis 2 Oral 3 Meningitis 4 Non-meningitis 5%S %R %S %I %R %S %I %R %S %I %R %S %I %R2001 537 87.3 12.7 99.1 0.9 0.0 87.3 8.8 3.9 95.2 3.4 1.5 98.5 0.6 0.9 3.52002 490 83.1 16.9 99.6 0.4 0.0 83.1 13.5 3.5 94.9 3.1 2.0 98.0 0.4 1.6 5.12003 523 83.6 16.4 98.9 1.2 0.0 83.6 9.0 7.5 88.0 8.4 3.6 96.4 1.9 1.7 7.12004 545 81.8 18.2 98.5 1.5 0.0 81.8 8.1 10.1 87.2 9.7 3.1 96.9 2.4 0.7 5.32005 492 82.9 17.1 98.6 1.4 0.0 82.9 10.0 7.1 90.5 6.5 3.1 97.0 1.7 1.4 6.72006 522 84.1 15.9 98.9 1.0 0.2 84.1 8.1 7.9 90.0 7.3 2.7 97.3 1.7 1.0 4.42007 555 77.7 22.3 99.1 0.7 0.2 77.7 16.0 6.3 86.0 11.4 2.7 97.3 1.1 1.6 6.12008 630 77.9 22.1 99.5 0.5 0.0 77.9 14.6 7.5 84.9 10.0 5.1 94.9 3.0 2.1 5.92009 665 82.3 17.7 99.7 0.3 0.0 82.3 12.3 5.4 91.1 6.9 2.0 98.1 1.4 0.6 5.32010 514 81.9 18.1 99.0 1.0 0.0 81.9 12.1 6.0 91.8 6.2 1.9 98.1 0.4 1.6 5.41 Penicillin meningitis interpretations: susceptible (S), MIC ≤0.06 mg/L; resistant (R), MIC ≥0.12 mg/L; no intermediate category.2 Penicillin non-meningitis (parenteral treatment) interpretations: susceptible (S), MIC ≤2 mg/L; intermediate (I), MIC 4 mg/L; resistant (R), MIC ≥8 mg/L.3 Penicillin non-meningitis (oral treatment) interpretations: susceptible (S), MIC ≤0.06 mg/L; intermediate (I), MIC 0.12-1 mg/L; resistant (R), MIC ≥2 mg/L.4 Cefotaxime meningitis interpretations: susceptible (S), MIC ≤0.5 mg/L; intermediate (I), MIC 1 mg/L; resistant (R), MIC ≥2 mg/L.5 Cefotaxime non-meningitis interpretations: susceptible (S), MIC ≤1 mg/L; intermediate (I), MIC 2 mg/L; resistant (R), MIC ≥4 mg/L.6 Multidrug resistant, that is, resistant to penicillin (meningitis interpretation) and three additional antibiotics.MDR 6Invasive pneumococcal disease 37 September 2011in NZ, 2010
Page 1 and 2: INVASIVE PNEUMOCOCCAL DISEASEIN NEW
Page 3 and 4: DISCLAIMERThis report or document (
Page 5 and 6: CONTENTSSUMMARY ...................
Page 7 and 8: SUMMARYA 4-dose schedule of the 7-v
Page 9 and 10: 1. INTRODUCTIONPrior to 2009, the n
Page 11 and 12: Data analyses were performed with S
Page 13 and 14: 3. RESULTSIn 2010, 535 IPD cases we
Page 15 and 16: The all-age rate of IPD in 2010 (12
Page 17: 3.4 Disease incidence by ethnicityT
Page 20 and 21: 3.7 Risk factors among IPD casesThe
Page 23 and 24: 3.10 Serotype distributionTable 9.
Page 25 and 26: Rate per 100 000The rate of disease
Page 27 and 28: 3.11 Antimicrobial susceptibilityTa
Page 29 and 30: Percent of penicillin-resistant iso
Page 31 and 32: type most frequently reported to ha
Page 33 and 34: REFERENCES1 Green MJ, Cawley PFM. I
Page 35 and 36: Appendix 1. Laboratory criteria upo
Page 37 and 38: Appendix 3. Rates of invasive pneum
Page 39 and 40: Appendix 5.2010Risk factors among i
Page 41 and 42: Appendix 7. Serotypes among invasiv
Page 43: Appendix 9. Serotype 1 invasive pne
Page 47 and 48: Appendix 13. Penicillin and cefotax
Page 49: Appendix 15. Trends in penicillin r

Invasive Pneumococcal Disease in New Zealand, 2010

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?